Comparative Pharmacology
Head-to-head clinical analysis: IMDUR versus NITROMIST.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IMDUR versus NITROMIST.
IMDUR vs NITROMIST
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Isosorbide mononitrate is a nitrate vasodilator that relaxes vascular smooth muscle via conversion to nitric oxide (NO), which activates guanylate cyclase, increasing cGMP levels, leading to vasodilation. It primarily dilates veins (venodilation) with lesser effects on arteries, reducing preload and afterload, thereby decreasing myocardial oxygen demand.
Nitroglycerin is a prodrug that releases nitric oxide (NO) which activates guanylyl cyclase, increasing cGMP in smooth muscle cells, leading to vasodilation primarily of venous capacitance vessels and coronary arteries.
Initial: 30-60 mg orally once daily; titrate to 120 mg once daily as tolerated. Maximum: 240 mg once daily.
1-2 sprays (0.4-0.8 mg) sublingually or intraorally at onset of angina, may repeat every 5 minutes up to 3 doses. Prophylaxis: 1 spray (0.4 mg) 5-10 minutes before activity.
None Documented
None Documented
Terminal elimination half-life of isosorbide mononitrate is approximately 5 hours. This supports once-daily dosing for IMDUR (extended-release formulation) due to prolonged absorption phase.
2–3 minutes for nitroglycerin; rapid metabolism results in short terminal half-life. Clinically, effects dissipate within 30 minutes of discontinuation.
Isosorbide dinitrate (IMDUR active metabolite? Actually IMDUR is isosorbide mononitrate, the active metabolite of isosorbide dinitrate. For isosorbide mononitrate: renal excretion is approximately 96% as metabolites, with about 2% unchanged; biliary/fecal excretion is minimal, <2%.
Renal excretion of inactive metabolites accounts for >80% of elimination; biliary/fecal excretion is minimal (<15%).
Category C
Category C
Nitrate Vasodilator
Nitrate Vasodilator